Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

Clinical Trial Phase Eligible Participant Official Title Drugs in Trial Location
NCT02855944IIIRecurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy)ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerView DrugsColorado, Georgia
Drug(s) in Trial Other Drug Names Main Known Action
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
NCT03398655IIIPlatinum resistant ovarian cancerA Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian CancerView DrugsArizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Montana, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Vermont, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
Ofranergene ObadenovecVB-111Endothelin promoter-apoptotic receptor gene therapy
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT02091141IIaAdvanced solid tumors with ALK mutations or high TMBMy Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These AgentsView DrugsArizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota, Missouri, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Dakota, Tennessee, Texas, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
AlectinibALK inhibitor CH5424802, Alecensa, anaplastic lymphoma kinase inhibitor CH5424802, AF802ALK kinase inhibitor
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
NCT02584478IIaRecurrent ovarian cancerA Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)View DrugsCalifornia, Florida, Louisiana, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AnlotinibAL3818VEGFR2/3 kinase inhibitor
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT02419417IIaPlatinum resistant or refractory ovarian cancer with BRCA1/2 mutationsA Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic MalignanciesView DrugsCalifornia, Colorado, Massachusetts, Oregon, Pennsylvania, South Carolina
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986158BET inhibitor BMS-986158BET inhibitor
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02502266II/IIIPlatinum resistant or refractory high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutated ovarian cancerA Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)View DrugsAlabama, Alaska, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
CediranibAZD2171, Cediranib maleate, RecentinVEGFR1-3 kinase inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT02272998IIAdvanced solid tumors with FGFR1-4, PDGFRa, Kit, RET, FLT3, or Abl1 alterationsPhase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1)View DrugsOhio
Drug(s) in Trial Other Drug Names Main Known Action
Ponatinibmultitargeted tyrosine kinase inhibitor AP24534, Iclusig, AP24534Multi-targeted kinase inhibitor
NCT02079740IIAdvanced solid tumors with KRAS or NRAS mutations (in expansion)An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid TumorsView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
NavitoclaxBcl-2 Family Protein Inhibitor ABT-263, A-855071.0, ABT-263Bcl-2, Bcl-XL, and Bcl-w inhibitor
TrametinibMekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212MEK1/2 inhibitor
NCT01037790IIAdvanced solid tumors with CCND1/2 amplification, CDK4/6 mutation, or other G1/S alterationsPhase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With CancerView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitor
NCT01953926IIAdvanced solid tumors with activating HER2 mutationsAn Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification.View DrugsAlabama, Arizona, California, Delaware, Florida, Georgia, Illinois, Louisiana, Massachusetts, Minnesota, Missouri, New York, Ohio, Pennsylvania, South Carolina, Tennessee, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
NeratinibHKI-272, PD272EGFR, HER2, HER4 kinase inhibitor
NCT02203513IIRecurrent high grade serous or endometrioid or germline BRCA1/2-mutated ovarian cancerA Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian CancerView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
Prexasertibcheckpoint kinase 1 inhibitor LY2606368, LY2606368Chk1/2 inhibitor
NCT02312245IIPlatinum resistant or refractory ovarian cancerAvatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube CancersView DrugsArizona, Florida, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitor
NCT02568267IIAdvanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangementsAn Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene RearrangementsView DrugsArizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New York, North Carolina, Ohio, Oregon, Texas, Utah, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action
EntrectinibTrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RXDX-101ALK, TRK, ROS1 kinase inhibitor
NCT02693535IIAdvanced solid tumors with molecular alterations in AKT1, ALK, ATM, BRAF, BRAFV600E/D/K/R, BRCA1/2, CDK4, CDK6, CDKN2A, CSF1R, ERBB2, FGFR1-3, FLT-3, KIT, MET, MLH1, MSH2, MSH6, mTOR, PALB2, PDGFR, PDGFRB, PMS2, POLD1, POLE, RAF-1, RET, ROS1, TSC1/2, VEGFR, high MSI, high TMBTargeted Agent and Profiling Utilization Registry (TAPUR) StudyView DrugsAlabama, Arizona, California, Florida, Georgia, Hawaii, Illinois, Indiana, Massachusetts, Michigan, Nebraska, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, South Dakota, Texas, Utah, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitor
AfatinibBIBW 2992 MA2, Gilotrif, Afatinib dimaleateEGFR, HER2, HER4 kinase inhibitor
CobimetinibXL518, GDC-0973, CotellicMEK1 inhibitor
Crizotinibc-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkoric-Met and ALK kinase inhibitor
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitor
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
PertuzumabPerjeta, monoclonal antibody 2C4, rhuMAb2C4HER2 dimerization inhibitor
RegorafanibBAY73-4506, multikinase inhibitor BAY 73-4506, StivargaMulti-targeted RTK inhibitor
SunitinibSutent, Sunitinib malateVEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit
TalazoparibTalazoparib Tosylate, BMN-673, MDV3800PARP inhibitor
TemsirolimusTorisel, CCI-779mTOR inhibitor
TrastuzumabHerceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal AntibodyHER2 antagonist
VemurafenibRO5185426, PLX4032, ZelborafBRAF kinase inhibitor
NCT02465060IIAdvanced solid tumors with alterations in AKT, BRAF, cKIT, CDK4 AMP, CDK6 AMP, EGFR, ERBB2 AMP, FGFR1-4, FGFR1-4 AMP, MET, MET AMP, mTOR, NTRK1-3, PIK3CA, PTCH1, PTEN, SMO, TSC1/2Molecular Analysis for Therapy Choice (MATCH)View DrugsAlabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action
AfatinibBIBW 2992 MA2, Gilotrif, Afatinib dimaleateEGFR, HER2, HER4 kinase inhibitor
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitor
Crizotinibc-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkoric-Met and ALK kinase inhibitor
Erdafitinibpan-FGFR tyrosine kinase inhibitor JNJ-42756493pan-FGFR kinase inhibitor
IpatasertibGDC-0068, Akt Inhibitor GDC-0068, RG7440pan-AKT inhibitor
LarotrectinibTrk inhibitor LOXO-101pan-Trk kinase inhibitor
OsimertinibTagrisso, AZD9291, EGFR inhibitor AZD9291, MereletinibEGFR kinase inhibitor
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitor
PertuzumabPerjeta, monoclonal antibody 2C4, rhuMAb2C4HER2 dimerization inhibitor
SapanisertibINK128, TORC1/2 Inhibitor INK128, TORC1/2 Inhibitor MLN0128, MLN0128, TAK-228TORC1/2 kinase inhibitor
SunitinibSutent, Sunitinib malateVEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit
TrastuzumabHerceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal AntibodyHER2 antagonist
Trastuzumab emtansinetrastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansineADC: anti-HER2 + microtubule destabilizer (DM1)
UlixertinibBVD-523, ERK inhibitor BVD-523ERK inhibitor
VismodegibHedgehog antagonist GDC-0449, Erivedge, GDC-0449Smoothened antagonist
NCT02628067IIAdvanced solid tumors with high MSIA Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)View DrugsCalifornia, Colorado, Florida, Maryland, Massachusetts, New Jersey, New Mexico, Texas
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT02576444IIAdvanced solid tumors with AKT, ARID1A, ATM, CDKN2A, CHEK2, IDH1/2, KRAS, MRE11A, PIK3CA, PTEN, TP53 and other HDR gene mutationsA Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid TumorsView DrugsConnecticut, Massachusetts, Ohio, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
CapivasertibAkt inhibitor AZD5363pan-AKT inhibitor
CeralasertibAZD6738, ATR kinase inhibitor AZD6738ATR kinase inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT01827384IIAdvanced solid tumors with mutations in BRAF, KRAS, NRAS, NF1, PIK3CA, AKT1, MTOR, FBXW7, PTEN, ATM, ATR, ERCC1, MLH1, MSH2, NBN, RAD51, PARP1/2,TP53Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid TumorsView DrugsColorado, Georgia, Kentucky, Maryland, Missouri, New Jersey, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
CarboplatinParaplatin, NovoplatinumDNA damaging agent
EverolimusAfinitor, Certican, RAD001, ZortressmTOR inhibitor
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agent
TrametinibMekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212MEK1/2 inhibitor
VeliparibABT-888PARP inhibitor
NCT02554812IIAdvanced solid tumors (in ovarian expansion)A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced MalignanciesView DrugsCalifornia, District of Columbia, Florida, Iowa, Michigan, New York, North Carolina, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
PD-0360324anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324CSF1R antagonist and tumor-associated macrophage inhibitor
PF-04518600anti-OX40 antibody PF-04518600Stimulates OX40 to increase T cell activation and immune response
NCT02832167IIAdvanced solid tumorsAn Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic MalignanciesView DrugsArizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02571725IIRecurrent ovarian cancer with germline BRCA1/2 mutations (no prior anti-CTLA-4 mAb)A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian CancerView DrugsFlorida, New Mexico, Ohio, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
OlaparibAZD2281, LynparzaPARP inhibitor
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT02873962IIPlatinum resistant or partially sensitive ovarian cancerA Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal CancerView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
NCT01851369IIAdvanced solid tumors and granulosa cell ovarian cancer (in expansion)A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and LymphomasView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
MethoxyamineTRC102Base excision repair inhibitor
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agent
NCT02901899IIPlatinum resistant ovarian cancerAn Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian CancerView DrugsIllinois
Drug(s) in Trial Other Drug Names Main Known Action
GuadecitabineDNA methyltransferase inhibitor SGI-110, SGI-110DNA methylation inhibitor
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cells
NCT02364713IIPlatinum resistant, refractory or persistent ovarian cancer (disease outside the peritoneal cavity)A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal CancerView DrugsArizona, Florida, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action
MV-NISoncolytic measles virus encoding thyroidal sodium iodide symporterInduces immune response and tumor cell lysis
NCT02873975IIAdvanced solid tumors with MYC or CCNE1 amplification, Rb loss, or FBXW7, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATR, ATM, CHEK2, Fanconi anemia pathway mutationsA Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair DeficiencyView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
Prexasertibcheckpoint kinase 1 inhibitor LY2606368, LY2606368Chk1/2 inhibitor
NCT02843165IIAdvanced solid tumors with lesion treatable with radiation therapyRandomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic DiseaseView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
IpilimumabAnti-Cytotoxic T-Lymphocyte-Ass